reach2: what patients with steroid-refractory acute gvhd respond best to ruxolitinib?
Published 4 years ago • 175 plays • Length 4:58Download video MP4
Download video MP3
Similar videos
-
3:14
reach2 study: what is the risk of losing response to ruxolitinib over time?
-
7:31
case 2: treating steroid-refractory acute gvhd
-
2:24
case 2: steroid-refractory acute graft-versus-host disease
-
4:46
reach3 study: should ruxolitinib become soc for steroid-dependent or refractory chronic gvhd?
-
7:47
case 2: treating steroid-refractory acute graft-versus-host disease
-
3:56
next steps in the treatment of acute gvhd
-
0:48
evaluating the role of ruxolitinib as treatment of graft-versus-host disease
-
4:28
what are the current treatment recommendations for acute gvhd and the promotion of the gvl effect?
-
53:07
new perspectives in acute and chronic gvhd
-
5:03
acute gvhd: grade, risk, and prophylaxis
-
12:11
ecp: looking to the future
-
2:36
phase ii study of pre-, during-, and post-transplant ruxolitinib for patients with myelofibrosis
-
4:38
phase i study of neihulizumab in patients with sr-agvhd or tr-agvhd
-
4:02
the benefits of gvhd risk stratification
-
2:03
use of rstsh for distant metastatic disease
-
2:21
primary findings from the phase 3, randomized reach3 study
-
6:17
key communications on gvhd at eha 2021
-
3:42
graft versus host disease: how to treat it?
-
5:12
phase ib/ii study of ptcy, abatacept & short-course tacrolimus for gvhd prevention following pbsct